$CELU News

Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement

Celularity Regains Nasdaq Compliance

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Celularity Q1 EPS $0.02 Up From $(0.84) YoY, Sales $3.846M Down From $11.426M YoY

Celularity Announces Naveen Jain to Join Board of Directors

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Celularity Announces Initial Closing Generating Over $10M In Gross Cash Proceeds From Private Placement Of Senior Secured Convertible Notes And Warrants

Celularity Says It Regained Compliance With Nasdaq Minimum Bid Price And Market Value Of Listed Securities Rules; Delinquent Periodic Filing Deficiency Remains Outstanding

Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity

Why Is Celularity Stock Gaining Thursday?

Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

Reported Earlier: Celularity And MuseCell Innovations Expand U.S. Manufacturing Collaboration, With Potential For $300M+ In Purchases Over Five Years

Celularity To Begin U.S. Production Of MuseCell Innovations' Dezawa MuseCells At Its New Jersey Facility

Celularity Provides Update Regarding Nasdaq Listing Compliance

Celularity Secures $1M Secured Loan From Philip & Daniele Barach Family Trust On June 29, 2026

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Celularity Releases CEO Letter to Shareholders

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Noncompliance Notice